Grufity logo
Grufity logo
SELB

SELB - Selecta Biosciences Inc Stock Price, Fair Value and News

$0.84-0.01 (-1.18%)
Market Closed as of 12 Jan 2024, 04:00 pm ET

Price Targets

SELB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SELB Price Action

SELB RSI Chart

SELB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SELB Valuation

Market Cap

24.0M

Price/Earnings (Trailing)

-0.16

Price/Sales (Trailing)

8.57

EV/EBITDA

0.68

Price/Free Cashflow

-0.31

SELB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

SELB Fundamentals

SELB Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

27.37%

Rev. Growth (Qtr)

109.51%

SELB Earnings

Earnings (TTM)

-151.8M

Earnings Growth (Yr)

-121.24%

Earnings Growth (Qtr)

57.68%

SELB Profitability

EBT Margin

-4987.31%

Return on Equity

102.47%

Return on Assets

-52.63%

Free Cashflow Yield

-322.69%

SELB Investor Care

Shares Dilution (1Y)

10.20%

Diluted EPS (TTM)

-5.85

Revenue & Growth

How Selecta Biosciences Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
202529.9M20.9M11.8M2.8M
202425.9M54.1M47.9M38.9M
202382.7M48.7M34.5M26.0M
2022108.0M127.6M123.9M110.8M
202132.0M47.3M67.1M85.1M
20209.2M11.6M14.1M16.6M
20192.9M4.8M-6.7M
2018---973.0K
20176.1M4.1M2.2M207.0K
20167.1M7.8M7.3M8.1M
20153.8M4.5M5.3M6.0M
2014---3.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Selecta Biosciences Inc

SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://selectabio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES64

Selecta Biosciences Inc Frequently Asked Questions

SELB is the stock ticker symbol of Selecta Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Mar 31 2026, market cap of Selecta Biosciences Inc is 23.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Mar 31 2026, SELB's PE ratio (Price to Earnings) is -0.16 and Price to Sales (PS) ratio is 8.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SELB PE ratio will change depending on the future growth rate expectations of investors.